Abstract | BACKGROUND:
Sex hormone deficiency is the most common cause of bone loss. Reduced bone mass and an increased risk for osteoporotic fractures have been described in hypogonadal subjects of both sexes. We present here the results of treating two patients showing abnormal sexual differentiation (an XX male and an XY female), who suffered from bone loss related to sex hormone deficiency, with cross genotype sex hormones. SUBJECTS AND METHODS: RESULTS: Before treatment both patients had low sex hormones and highly elevated gonadotropins. As a result of treatment urine hydroxyproline excretion decreased from 45 and 26.7 mg/g creatinine to 15 and 15.9 mg/g creatinine in patients 1 and 2 respectively. In patient 1, lumbar BMD rose from 0.912gr/cm2 to 0.976gr/cm2 and femoral neck BMD rose from 0.716gr/cm2 to 0.836gr/cm2 after 4 years of treatment. In patient 2, lumbar BMD rose from 0.717gr/cm2 to 0.815gr/cm2 and the femoral neck BMD rose from 0.509gr/cm2 to 0.635gr/cm2 after 27 months of treatment. CONCLUSIONS: Phenotypically-matched sex hormone therapy in patients with abnormal sexual differentiation is essential not only to maintain external appearance but also for the preservation of bone mass.
|
Authors | I Vered, I Kaiserman, B A Sela, J Sack |
Journal | The Journal of clinical endocrinology and metabolism
(J Clin Endocrinol Metab)
Vol. 82
Issue 2
Pg. 576-8
(Feb 1997)
ISSN: 0021-972X [Print] United States |
PMID | 9024257
(Publication Type: Journal Article)
|
Chemical References |
- Estrogens
- Testosterone
- Hydroxyproline
|
Topics |
- Adult
- Bone Density
- Estrogens
(therapeutic use)
- Female
- Genotype
- Humans
- Hydroxyproline
(urine)
- Hypogonadism
(complications, drug therapy, genetics)
- Male
- Osteoporosis
(drug therapy, etiology, genetics)
- Testosterone
(therapeutic use)
- Treatment Outcome
|